Drug Search Results

Tideglusib

Alternative Names: tideglusib, np031112, amo-02, amo 02, amo02, np-031112
Latest Update: 2024-06-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: GSK3B Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Noscira
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tideglusib

Countries in Clinic: Australia, Canada, New Zealand, United Kingdom, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Myotonic Dystrophy

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
REACH CDM X	P3	Recruiting	Myotonic Dystrophy	2025-03-28	42%
REACH CDM	P3	Completed	Myotonic Dystrophy	2023-04-04	42%

Recent News Events

Date	Type	Title
06/01/2024	PubMed	The redox-sensitive GSK3β is a key regulator of glomerular podocyte injury in type 2 diabetic kidney disease.
05/15/2024	PubMed	GSK-3: An "Ace" Among Kinases.
05/02/2024	News Article	AMO Pharma Completes Meeting with U.S. FDA and Outlines Plans to Advance Clinical Development of AMO-02 (tideglusib) in Treatment of Myotonic Dystrophy
04/26/2024	PubMed	Tunable polymer-peptide hybrids for dentin tissue repair.
02/15/2024	News Article	AMO Pharma Announces Collaboration with Population Health Research Institute to Advance Proof of Concept Clinical Trial to Assess Efficacy of Tideglusib in Treatment of Arrhythmogenic Cardiomyopathy
09/19/2023	News Article	AMO Pharma Announces Preclinical Data Showing AMO-02 Improves Muscle Function, Glucose Handling and CNS function in Mouse Models of Duchenne Muscular Dystrophy
09/06/2023	News Article	AMO Pharma Announces Affirming Data from REACH-CDM Clinical Trial for AMO-02 in Treatment of Myotonic Dystrophy

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions